Azithromycin, one of the most widely prescribed antibiotics in pediatric medicine, may ease persistent wheezing after severe pneumonia not by killing microbes but by switching off a specific epigenetic program inside lung immune cells. That is the central finding of a new study published in Pediatric Research, in which a team at Guizhou Children’s Hospital, affiliated with Zunyi Medical University, traced the drug’s benefit to its ability to inhibit an enzyme called SETD1B and the histone modification it drives, thereby rebalancing the inflammatory state of alveolar macrophages. The work offers a mechanistic explanation for a clinical effect that clinicians have long observed but struggled to explain, and it points to a potential treatment strategy for a condition that currently has no targeted therapy.
The condition in question, post-inflammatory wheezing, is a common and troubling sequel of acute pulmonary infection in young children. After an episode of severe pneumonia, many children continue to wheeze for weeks or months, a sign of persistent airway inflammation and dysfunction that can presage recurrent wheezing disorders and, in some children, the later development of asthma. Existing management is largely symptomatic, and the researchers behind the new study emphasize in their impact statement that there is currently no effective treatment specifically for post-inflammatory wheezing. Understanding why the airway stays inflamed after the initial infection has cleared is therefore a pressing question in pediatric respiratory medicine.
To address it, the team enrolled 239 children who had been hospitalized with severe pneumonia and divided them into two groups: those who went on to develop post-inflammatory wheezing and those who did not. The children with wheezing were then assigned to receive either routine symptomatic treatment alone or routine treatment plus a five-day course of azithromycin at a dose of 10 milligrams per kilogram of body weight per day. The researchers compared clinical outcomes between the groups and also examined cellular and molecular markers in bronchoalveolar lavage fluid, the liquid retrieved from the deep airways during fiberoptic bronchoscopy, which provides a direct window into the immunology of the lung.
The comparison revealed a distinctive inflammatory signature in the wheezing children. Their lavage fluid showed an abnormal cellular composition, elevated levels of the pro-inflammatory signaling molecule interleukin-6, and reduced levels of the anti-inflammatory cytokine interleukin-10, a pattern indicating that the immune balance of the airway had tipped toward attack rather than resolution. Crucially, the researchers also found significantly increased expression of SETD1B, a member of the SET domain family of histone methyltransferases, along with elevated levels of H3K4me3, the trimethylated form of histone H3 lysine 4 that SETD1B deposits. Histone modifications such as this one regulate which genes are accessible for transcription, meaning that the wheezing children’s airway immune cells appeared to be carrying an epigenetic imprint that kept inflammatory programs switched on.
When the children received azithromycin on top of routine care, the clinical benefits were clear. The drug shortened the duration of wheezing, reduced the length of hospital stay, and lowered medical costs compared with symptomatic treatment alone. Perhaps the most revealing result, however, came from a subgroup analysis. The researchers found no significant difference in clinical efficacy between children who tested positive for Mycoplasma pneumoniae, a bacterium that azithromycin can kill, and those who tested negative. If the drug were working purely as an antibiotic, mycoplasma-negative children should have derived little benefit. Instead, the benefit was equivalent in both groups, confirming that azithromycin’s therapeutic effect in post-inflammatory wheezing is independent of its anti-mycoplasma activity and must arise from some other property of the molecule.
That other property, the study suggests, is immunomodulation acting through the epigenetic machinery. Macrolide antibiotics like azithromycin have long been known to exert anti-inflammatory effects beyond their antimicrobial role, an observation that has fueled their use in chronic inflammatory airway diseases such as cystic fibrosis, diffuse panbronchiolitis, and chronic obstructive pulmonary disease, and that prompted intense interest in the drug during the COVID-19 pandemic. But the specific molecular targets of this immunomodulation have remained only partially mapped. The new work connects the drug to a precise epigenetic axis, and it builds on the same group’s earlier finding that azithromycin can attenuate wheezing by inhibiting a different histone mark, H3K27me3, mediated by the enzyme EZH2, suggesting that the drug’s anti-inflammatory reach extends across multiple histone methylation systems.
To test the mechanism directly, the researchers turned to an in vitro model. They exposed rat alveolar macrophages, the resident immune cells of the lung’s air sacs, to lipopolysaccharide, a bacterial molecule that reliably triggers a strong inflammatory response. The LPS challenge induced hypermethylation of H3K4me3 driven by SETD1B, disturbed the production of inflammatory cytokines, and pushed the macrophages toward the M1 polarization state, the classically activated, pro-inflammatory phenotype that floods tissue with cytokines. Macrophage polarization, the process by which these cells shift between the inflammatory M1 state and the tissue-repairing M2 state, is increasingly recognized as a central player in inflammatory lung disease, and an excess of M1 polarization is a plausible driver of the persistent airway inflammation seen in wheezing children.
The decisive experiment involved comparing azithromycin with WDR5-0103, a small-molecule inhibitor that specifically blocks SETD1B function. When the LPS-stimulated macrophages were treated with either azithromycin or WDR5-0103 alone, the drug and the inhibitor each significantly reversed the full spectrum of LPS-induced abnormalities: the SETD1B-driven H3K4me3 hypermethylation, the cytokine imbalance, and the M1-skewed polarization. When the two were combined, however, no additional benefit emerged. This lack of synergy is mechanistically telling. If azithromycin and the SETD1B inhibitor were acting through separate pathways, combining them should have produced an additive effect. The absence of one indicates that the two interventions converge on the same target, placing SETD1B-mediated H3K4me3 methylation squarely on the pathway through which azithromycin exerts its anti-inflammatory effect in these cells.
Taken together, the clinical and laboratory findings sketch a coherent causal chain. Severe pulmonary infection elevates SETD1B expression in airway immune cells, which trims excess H3K4me3 marks onto histones near inflammatory genes, keeping them in a transcriptionally active state. This epigenetic drift biases alveolar macrophages toward the M1 phenotype, sustains high interleukin-6 output, suppresses interleukin-10, and maintains the airway in a state of chronic low-grade inflammation that manifests as wheezing. Azithromycin interrupts this chain at its epigenetic root, restoring the M1/M2 balance, normalizing the cytokine milieu, and allowing the airway inflammation to resolve, with the clinical result that children wheeze for less time and leave the hospital sooner.
The implications extend beyond a single drug and a single disease. The study demonstrates that a familiar, inexpensive, and well-characterized antibiotic can be repurposed as an epigenetic modulator for a pediatric condition with no current targeted treatment, and it identifies SETD1B and H3K4me3 as potential biomarkers for identifying which children with post-infectious wheezing carry an active epigenetic inflammatory program. It also raises questions that future work will need to answer, including whether the epigenetic changes seen in lavage fluid predict long-term asthma risk and whether shorter or longer azithromycin regimens might optimize the immunomodulatory effect while minimizing concerns about antibiotic resistance. For now, the study provides the strongest mechanistic account yet of why a five-day course of azithromycin can quiet a child’s wheezing long after the infection that started it has been cleared, and it suggests that the key to treating some chronic airway inflammation lies not in fighting microbes but in editing the inflammatory memory that immune cells carry within their chromosomes.
Subject of Research: Epigenetic and immunomodulatory mechanisms of azithromycin in pediatric post-inflammatory wheezing
Article Title: Azithromycin alleviates post-inflammatory wheezing in children by inhibiting SETD1B-mediated histone H3K4me3 methylation and macrophage polarization
Article References: Wang, L., Peng, C., Wu, S., Tang, T., Lin, Q., & Qin, H. (2026). Azithromycin alleviates post-inflammatory wheezing in children by inhibiting SETD1B-mediated histone H3K4me3 methylation and macrophage polarization. Pediatric Research. https://doi.org/10.1038/s41390-026-05444-z
Image Credits: AI Generated
DOI: 10.1038/s41390-026-05444-z
Keywords: azithromycin, post-inflammatory wheezing, SETD1B, H3K4me3, histone methylation, macrophage polarization, alveolar macrophages, interleukin-6, interleukin-10, pediatric pneumonia, epigenetics, immunomodulation
